ASH 2022 | The impact of the addition of anti-CD38 monoclonal antibodies to the frontline treatment of myeloma
Hamza Hashmi
• 10 Dec 2022
Hamza Hashmi, Medical University of South Carolina, Charleston, SC, explains how the addition of anti-CD38 monoclonal antibodies to backbone regimens has led to improved sustained measurable residual disease (MRD) negativity, progression-free survival, and overall survival (OS) in patients with newly diagnosed multiple myeloma. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Speakers Bureau; GSK: Speakers Bureau; KARYOPHARM: Speakers Bureau; JANSSEN: Consultancy; BMS: Consultancy.
